advertisement
Huang C 20
Showing records 1 to 20 | Display all abstracts from Huang C106727 Protective effect of leukemia inhibitory factor on the retinal injury induced by acute ocular hypertension in rats
Lv J
Experimental and therapeutic medicine 2023; 25: 19
105803 Geographic and socioeconomic access disparities to Phase 3 clinical trials in ophthalmology in the United States
Soares RR
Eye 2023; 37: 1822-1828
105280 Sustained release of brimonidine from BRI@SR@TPU implant for treatment of glaucoma
Zhao Y
Drug Delivery 2022; 29: 613-623
105803 Geographic and socioeconomic access disparities to Phase 3 clinical trials in ophthalmology in the United States
Huang C
Eye 2023; 37: 1822-1828
105280 Sustained release of brimonidine from BRI@SR@TPU implant for treatment of glaucoma
Huang C
Drug Delivery 2022; 29: 613-623
106727 Protective effect of leukemia inhibitory factor on the retinal injury induced by acute ocular hypertension in rats
Gao R
Experimental and therapeutic medicine 2023; 25: 19
105280 Sustained release of brimonidine from BRI@SR@TPU implant for treatment of glaucoma
Zhang Z
Drug Delivery 2022; 29: 613-623
105803 Geographic and socioeconomic access disparities to Phase 3 clinical trials in ophthalmology in the United States
Sharpe J
Eye 2023; 37: 1822-1828
106727 Protective effect of leukemia inhibitory factor on the retinal injury induced by acute ocular hypertension in rats
Wang Y
Experimental and therapeutic medicine 2023; 25: 19
105803 Geographic and socioeconomic access disparities to Phase 3 clinical trials in ophthalmology in the United States
Sharpe J
Eye 2023; 37: 1822-1828
106727 Protective effect of leukemia inhibitory factor on the retinal injury induced by acute ocular hypertension in rats
Huang C
Experimental and therapeutic medicine 2023; 25: 19
105803 Geographic and socioeconomic access disparities to Phase 3 clinical trials in ophthalmology in the United States
Cobbs L
Eye 2023; 37: 1822-1828
105280 Sustained release of brimonidine from BRI@SR@TPU implant for treatment of glaucoma
Hong J
Drug Delivery 2022; 29: 613-623
105803 Geographic and socioeconomic access disparities to Phase 3 clinical trials in ophthalmology in the United States
Gopal A
Eye 2023; 37: 1822-1828
105280 Sustained release of brimonidine from BRI@SR@TPU implant for treatment of glaucoma
Xu J
Drug Delivery 2022; 29: 613-623
106727 Protective effect of leukemia inhibitory factor on the retinal injury induced by acute ocular hypertension in rats
Wu R
Experimental and therapeutic medicine 2023; 25: 19
105280 Sustained release of brimonidine from BRI@SR@TPU implant for treatment of glaucoma
Sun X
Drug Delivery 2022; 29: 613-623
105803 Geographic and socioeconomic access disparities to Phase 3 clinical trials in ophthalmology in the United States
Rao W
Eye 2023; 37: 1822-1828
105280 Sustained release of brimonidine from BRI@SR@TPU implant for treatment of glaucoma
Sun J
Drug Delivery 2022; 29: 613-623
105803 Geographic and socioeconomic access disparities to Phase 3 clinical trials in ophthalmology in the United States
Samuelson A; Parikh D; Zhang Q; Bailey R; Dunn JP; Minor J; Moster ML; Penne RB; Shields C; Shukla AG; Shukla AG; Syed Z; Wisner D; Haller JA; Yonekawa Y
Eye 2023; 37: 1822-1828
